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Background & Aims: Corticosteroids are used as immunosuppres-
sants in patients with autoimmune disorders and transplant recipi-
ents. However, these drugs worsen hepatitis C virus (HCV)
recurrence after liver transplantation, suggesting that they may
directly exacerbate HCV infection.
Methods: The inﬂuence of immunosuppressive drugs on HCV repli-
cation, assembly, and entry was assessed in Huh-7.5 cells and pri-
mary human hepatocytes using cell culture- and patient-derived
HCV. Replication was quantiﬁed by immunoﬂuorescence, luciferase
assays, quantitative reverse-transcriptase polymerase chain reac-
tion, or core enzyme-linked immunosorbent assays. Expression of
HCV entry factors was evaluated by cell sorting and immunoblot
analyses.
Results: Glucocorticosteroids slightly reduced HCV RNA replication
but increased efﬁciency of HCV entry by up to 10-fold. This was inde-
pendent of HCV genotype but speciﬁc to HCV because vesicular sto-
matitis virus glycoprotein-dependent infection was not affected by
these drugs. The increase in HCV entry was accompanied by up-reg-
ulation of messenger RNA and protein levels of occludin and the
scavenger receptor class B type I – two host cell proteins required
for HCV infection;increase of entry by glucocorticosteroids was
ablated by RU-486, an inhibitor of glucocorticosteroid signalling.
Glucocorticosteroids increased propagation of cell culture-derived
HCV approximately 5- to 10-fold in partially differentiated human
hepatoma cells and increased infection of primary human hepato-
cytes by cell culture- and patient-derived HCV.
Conclusions: Glucocorticosteroides speciﬁcally increase HCV entry
by up-regulating the cell entry factors occludin and scavenger recep-
tor class B type I. Our data suggest that the potential effects of high-Journal of Hepatology 20
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Hepatitis C-associated liver failure is the leading indication for
liver transplantation (LT). Hepatitis C virus (HCV) re-infection of
the liver graft occurs immediately after transplantation with a
rapid increase in HCV RNA post-transplantation [1]. HCV recur-
rence is characterized by accelerated histological progression,
with up to 30% of patients developing cirrhosis after ﬁve years
following LT [1]. A prophylactic strategy for prevention of re-
infection is lacking and interferon-based antiviral therapies have
limited efﬁcacy and tolerability in LT recipients [2]. Thus, recur-
rent liver disease with poor outcome has become an increasing
problem facing hepatologists and transplant surgeons [2].
Viral and host factors contribute to HCV re-infection and pro-
gression of liver disease. Viral factors include efﬁciency of entry,
replication, and production of progeny virus. Host factors include
immune responses and graft- or donor-related factors. Advanced
donor age and the use of immunosuppression have been postu-
lated as risk factors for more rapid ﬁbrosis following LT [3].
Furthermore, the administration of high doses of glucocorticoster-
oids (GCs) appears to be associatedwith the severity of HCV recur-
rence, increased mortality, and graft loss in LT recipients [3].
To better understand the impact of immunosuppressive drugs
on HCV infection, an elegant study from Thomas Pietschmann’s
laboratory investigated the effect of GC, cyclosporin A, tacroli-
mus, mycophenolate sodium, basiliximab, evrolimus, and azathi-
oprine on the HCV life cycle [4]. To identify virus-drug
interactions, Ciesek et al. studied HCV entry, replication, and
assembly in permissive Huh-7.5 hepatoma cells and primary
human hepatocytes using HCV pseudoparticles and infectious
virions. Using this approach, Ciesek et al. uncovered that GCs
enhance HCV entry and dissemination into hepatocytes. Prednis-
olone (starting at 10–50 lg/ml) increased the efﬁciency of HCV
entry by up to 10-fold whereas the other immunosuppressive
compounds had no effect. The GC effect was independent of
HCV genotype but speciﬁc to HCV because vesicular stomatitis
virus glycoprotein-dependent infection was not affected by these
drugs. Although GC slightly affected HCV RNA replication, the
pronounced stimulation of HCV entry was dominant thus
increasing propagation of cell culture-derived HCV approxi-
mately 5- to 10-fold in partially differentiated human hepatoma10 vol. 53 j 1148–1150
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cells and increased HCV infection of primary human hepatocytes
[4]. Using kinetic studies of HCV infection, the authors provide
evidence that GCs accelerate the speed of HCV cell entry. Finally,
by using different densities of Huh7.5 cells infected with recom-
binant reporter viruses in the presence of prednisolone, the
authors demonstrate that GC enhanced HCV dissemination in a
cell-density-dependent manner [4].
HCV entry into hepatocytes is a complex andmultistep process
requiring several entry factors, including scavenger receptor class
B type I, CD81 and tight junction proteins claudin-1 (CLDN1), and
occludin (OCLN) (for review see [5,6]). To further investigate the
mechanisms mediating GC-induced enhanced viral entry, Ciesek
et al. analyzed the expression of HCV cell entry factors. While
expression of CD81, CLDN1 was not affected by GCs, expression
of SR-B1 and OCLN was increased in a dose-dependent manner.
The effects of glucocorticoids are mediated by the glucocorticoid
receptor [7]. The glucocorticoid receptor binds to speciﬁc DNASR-B1
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Fig. 1. Model of glucocorticoid-induced enhanced HCV entry into hepatocytes. HCV en
density lipoprotein receptor (LDL-R) represent putative attachment sites before the virus
CD81, claudin-1 (CLDN1), and occludin (OCLN). For CLDN1 both junctional and n
Glucocorticosteroids (GCs) are believed to enhance HCV entry by the following events [3]
complex binds to speciﬁc DNA sequences – the glucocorticoid-response element (GRE) –
genes including HCV cell entry factor occludin [8]. GCs also enhance SR-B1 gene expr
facilitates HCV entry into hepatocytes and viral dissemination [3]. Abbreviations: GC
GRE – glucocorticoid-response element, HCV – hepatitis C virus, SR-BI – scavenger recept
– occludin.
Journal of Hepatology 2010sequences – glucocorticoid-response elements – in the 50-ﬂanking
region of target genes and transactivates gene transcription [7].
Indeed, a glucocorticoid-response element was recently identiﬁed
within the OCLN gene [8]. Thus, transactivation of OCLN gene
expression by GCs [8] may be responsible for the enhanced entry
factor expression and viral entry (Fig. 1). In line with this interpre-
tation, Ciesek et al. report that ablation of GC signalling by RU-486
prevents up-regulation of OCLN and SR-BI and in turn also
enhancement of HCV cell entry.
What are the clinical implications of these ﬁndings? Viral cell
entry and dissemination are the very ﬁrst steps of HCV infection
and required for maintenance of chronic infection in the patient.
Furthermore, enhanced viral entry and escape from neutralizing
antibodies are key determinants of re-infection of the liver graft
during liver transplantation [9]. The ﬁndings of Ciesek et al. sug-
gest that the potential effects of high-dose GCs on viral load
in vivo may be due to increased HCV entry and dissemination.CLDN1
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try into hepatocytes is a multistep process: glycosaminoglycans (GAG) and low-
interacts with cell entry factors including scavenger receptor class B type I (SR-BI),
on-junctional forms have been described (for review see Zeisel et al. [6]).
: In the cytoplasm, GCs bind to the glucocorticoid receptor (GR). In the nucleus, the
and transactivates gene transcription with subsequent overexpression of response
ession by a yet unknown mechanism [3]. Overexpression of occludin and SR-BI
– glucocorticosteroid, GAG – glycosaminoglycans, GR – glucorticoid-receptor,
or class B type, CLDN1 – claudin 1, LDLR – low-density lipoprotein receptor; OCLN
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Based on their dose-dependent observations on GC-HCV interac-
tions obtained in cell culture models, the authors conclude that
steroid bolus treatment (>250 mg prednisolone/day) of HCV-
infected individuals, which results in plasma levels up to 50 lg/
ml, may foster virus dissemination through facilitation of virus
entry into hepatocytes, thus aggravating HCV recurrence. Indeed,
several studies demonstrated that high-dose steroid therapy
leads to a sudden and dramatic increase in viremia levels in the
early post-operative period [8]. Furthermore, a meta-analysis
suggests that immunosuppression regimens without steroids
are associated with a reduction in the severity of the recurrence
of hepatitis after LT [10].
Although further studies are needed to better understand the
mechanism of accelerated progression of HCV-induced liver dis-
ease in transplant patients, the ﬁndings of Ciesek et al. have
uncovered a novel mechanism in HCV-drug interactions playing
a role in this process. Enhanced HCV entry and dissemination
induced by high-dose GCs may not only have an important clin-
ical relevance for the understanding of the pathogenesis of HCV
infection but could provide a rationale for the development of
improved immunosuppressive therapies for the HCV-infected
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